Objective. Identifying pain generators in tissue deep in the skin can require uncomfortable, complicated, and invasive tests. We describe pilot studies testing the hypothesis that ultrasound image-guided, intense focused ultrasound (ig-iFU) can noninvasively and differentially stimulate the end of transected nerves in the residual limbs of amputee patients.
Introduction
A patient's pain may arise from readily identifiable peripheral sources via nociceptive pathways and/or amplify or occur primarily due to central sensitization. These factors can make pain diagnosis and treatment difficult. As part of a diagnostic armamentarium for either acute or chronic pain, physicians often perform evocative tests such as palpation in addition to imaging in order to try to locate, and hence identify, deep potential pain generators. Manual palpation (or its complement, anesthetizing via injection) of deep, potentially tender tissue also involves the intervening, generally superficial tissue, adding complexity to pain diagnosis. In addition, commonly used imaging studies may identify multiple candidate pain generators or find only normal-appearing tissue at the site of sensitivity, making diagnosis and treatment of pain more difficult. For example, 50% to 80% of people with amputations experience pain that arises through a combination of peripheral sources such as neuromas and peripheral and central sensitization. These significantly impact function and quality of life [1] [2] [3] [4] [5] [6] and generally have ineffective diagnoses and treatments despite extensive imaging [7, 8] . Neuromas after amputation occur quite commonly, appearing readily on ultrasound and magnetic resonance (MR) imaging. Determining whether a neuroma actually contributes to a patient's pain, however, requires stimulating the neuroma to see if stimulation reproduces the experienced pain; problematic for deep neuromas and currently impossible without stimulating intervening tissue that may also contribute to the patient's pain.
Therefore, a noninvasive means of stimulating small, deep, and potentially tender tissue could significantly improve the ability of a clinician to locate painful tissue, a step toward identifying or ruling out the existence of pathology at the site of tenderness.
The use of intense focused ultrasound (iFU) under image guidance may represent a viable method for identifying deep painful tissue. Our previous work shows that iFU can elicit differential responses to stimulation in diffusely inflamed and neuropathic rat paws [9] [10] [11] [12] . In addition, several researchers have shown that sufficiently intense iFU can generate sensations in healthy study participants when applied to superficial tissue [13] [14] [15] [16] . Moreover, we have applied it successfully to identify focal and subcutaneous sources of shoulder pain in humans [17] . Finally, we showed that iFU could stimulate a neuroma in a rat model while the rats were lightly anesthetized, eliciting a motor response to their stimulation, while the same intensity of ultrasound applied to control tissue failed to induce a motor response [11] .
Together, these results motivate the present study, which seeks to test the hypothesis that image-guided iFU can noninvasively stimulate transected nerve endings in the residual limbs of amputee patients who had undergone either standard amputation surgery or targeted nerve implantation, such that the stimulation differentiates the transected nerve ending from control tissue.
Materials and Methods

Patient Population
The Institutional Review Board of the University of Washington approved our human study. We recruited study participants from two groups of patients: those who had undergone lower limb amputation surgery using either standard techniques, where the transected nerve ending lies proximal to the end of the residual limb in soft tissue, or a targeted nerve implantation (TNI) technique [18] . Briefly, TNI consists of implanting the transected nerve ending into a secondary motor nerve point in muscle after partial surgical denervation at the time of amputation or during revision surgery.
Study participants were recruited via flyers at the Harborview Medical Center Amputation Clinic. Inclusion criteria were six or more months since lower limb amputation (transtibial, knee disarticulation, or transfemoral) and age 18 to 75 years. Exclusion criteria were current pressure ulcers, rashes, or open skin over residual limb, history of skin grafting or burns on residual limb, history of diabetes mellitus, cognitive or communication impairments that would impede participation in the testing procedures, history of muscle or nerve disease, including peripheral vascular disease, and evidence of alcohol or illicit drug use. We conducted studies on four TNI patients and seven standard amputation patients.
Ultrasound Device
Our iFU system consisted of a portable commercial diagnostic ultrasound imaging machine connected to an intense focused ultrasound stimulation transducer, hence called an image-guided iFU (ig-iFU) system. Figure 1 shows a schematic of the device and of its application. We described it in detail in Gellhorn et al. (2015) [17]-so we include here only a summary description.
Ultrasound Device-iFU Transducers
We created five 2.0 MHz iFU transducers, each with its focus at a different depth relative to the skin surface (0.4 cm, 1.3 cm, 2.45 cm, 2.75 cm, and 3.0 cm). For a given patient, we used one transducer to deliver individual single bursts of ultrasound lasting 0.1 seconds, driven by a power amplifier controlled by two function generators. Input voltage, translated into spatial and temporal average intensity, was calibrated in advance of experiments using a hydrophone in a water tank, and it was monitored during the experiment using an oscilloscope. Full details regarding calibration can be found in Gellhorn et al. (2015) [17] .
Ultrasound Device-Imaging System
Ultrasound image guidance was provided by a portable Sonosite M-Turbo ultrasound machine with a 13-6 MHz linear transducer whose imaging plane contained the iFU focus, as verified by an ultrasound needle hydrophone. Depths of the iFU transducers were marked on the screen of the Sonosite, such that we could see on the active ultrasound images the target of iFU stimulation.
Ultrasound Device-Integrated Ig-Ifu System
The imaging transducer was mounted within a custom housing that screwed onto the iFU transducers. This allowed us to image through a hole in the center of the iFU transducers, such that the imaging plane aligned directly with the iFU focus, verified in a water bath that included use of an ultrasound-sensitive needle hydrophone.
Study Procedures
Pain Questionnaires
After successful consent, all study participants completed three pain questionnaires. The first questionnaire [19] the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)-yielded a composite pain score on a scale of 0 to 24, such that scores higher than 12 pointed to the likelihood of neuropathic pain during the week prior to the study. Each participant also reported the intensity of their phantom limb pain and of their pain associated with the residual limb itself as experienced over the last 24 hours (numeric pain rating scale from 0 ¼ "no pain" to 10 ¼ "pain as bad as you can imagine").
Initial Ultrasound Imaging and Manual Palpation
After a given study participant completed their questionnaires, the physician palpated areas in the distal portion of their residual limb to identify a region that contained tender tissue. Next, the sonographer imaged the study participant's residual limb using only the ultrasound imaging transducer, in order to identify anatomical structures of interest within the tender region, always the transected nerve ending, with or without an observable neuroma ( Figure 2A ). The location and depth of the tender sites were noted to facilitate subsequent iFU stimulation with the appropriate iFU transducer under ultrasound image guidance. With regard to the contralateral limb, the sonographer imaged the major nerve that corresponded to the target nerve in the ipsilateral limb, recording the location and depth as above. The physician did not, however, palpate the contralateral limb.
iFU Stimulation of Targets in the Residual Limb
After the initial exploratory imaging described above, we selected in a serial fashion the target tissue (the transected nerve ending with or without an identifiable neuroma), then assembled the ig-iFU system using the A B Figure 1 A) Illustration of the ig-iFU device focused on a horizontal cross-section of a neuroma. B) Illustration of the ig-iFU device focused on a neuroma, using a three-dimensional view of the device with a sample B-mode image placed within the image.
iFU transducer with the appropriate depth of stimulation.
Using the ig-iFU system, we then relocated the target tissue site via ultrasound imaging and aligned the focus of the iFU transducer with the target ( Figure 2B ). We then applied or sham-applied iFU in three to five individual 0.1-second bursts, at approximately 1 Hz, to the target tissue in a manner blinded to the study participant.
We started with a low iFU intensity value (16 W/cm 2 ). After each actual or sham application, we asked the study participants if they felt any sensations associated with the application beyond that engendered by the touch of the device to the skin. If they did not feel any sensation with the iFU application, we increased the intensity and tried again. If they did indicate that they felt the stimulation, we repeated the iFU stimulation procedure using the same iFU intensity to verify the sensation. If they did not feel a sensation this second time, we increased the intensity of iFU stimulation and tried again. Once a study participant reported two consecutive sets of sensations (our definition of a "reliable" sensation) at the same intensity, we did not increase the intensity of iFU any further for that target. We define this intensity as the iFU threshold intensity value. For sites where we were unable to elicit a sensation as we raised the iFU intensity, we stopped our studies when we reached 1,032 W/cm 2 , the maximum output of the device. We then moved the focus of the ig-iFU device to control tissue approximately 1 cm superficial to the transected nerve ending, applying actual iFU stimulation to it with the same intensity that generated a sensation when applied to the transected nerve ending or to the maximum intensity of the device, as appropriate. We then applied that same intensity of iFU to the proximal portion of nerve anatomically associated with the transected nerve ending, again asking about any sensations experienced by the patient due to iFU stimulation.
Finally, when not constrained by patient fatigue, we repeated the entire iFU threshold determination process for the corresponding nerve in the study participant's intact, contralateral limb.
Results
Here we report our results as a summary of the individual cases for each study participant. In addition, Table 1 describes the results for each patient. Finally, in Figure 3 , we present scatterplots relating the observed iFU intensity threshold value to each of the phantom limb pain and residual limb pain scores for each study participant.
TNI Patients
In all four cases, we identified a neuroma and associated proximal nerve near the site of manual tenderness using diagnostic ultrasound imaging (Table 1) . (In one case, we identified two neuromas and associated proximal nerves.) For three of the four study participants, iFU stimulation of their neuroma elicited a sensation (tingling to nonpainful shocks), but only once did it include sensations of the phantom limb. For those same three cases, the proximal nerve to the neuroma had the same iFU threshold-induced stimulation threshold as the neuroma. One study participant experienced mild and transient pain. For two of the four study participants, application of iFU to an intact nerve contralateral to the transected nerve ending did not elicit any sensations, including for the study participant whose neuroma was insensitive to iFU stimulation. We did not attempt to determine an iFU stimulation threshold value for the contralateral nerve in the other two study participants. One study participant had two neuromas, each with different iFU stimulation threshold values. In contrast, another study participant also had two neuromas, each insensitive to iFU stimulation. 
Standard Amputation Patients
In three out of seven cases, we identified neuromas via ultrasound imaging at the site of palpable tenderness at the transected nerve ending (Table 1) .
For two study participants, the neuroma and proximal nerve had the same iFU threshold stimulation value. Those values differed substantially between these patients, however. In addition, the neuroma for the third patient was sensitive to iFU stimulation while the proximal nerve was not at the same iFU threshold value. In all of these cases, iFU stimulation generated phantom limb sensations. For two patients, we tried but failed to observe successful iFU stimulation of the intact nerve in the contralateral limb.
In the other four cases, we found only a transected nerve ending with diagnostic ultrasound imaging ( Table 1) . For these study participants, we determined the iFU threshold intensity value for the nerve ending itself, specifically at a point that offered an unambiguous imaging target. All four of these study participants had transected nerve endings sensitive to iFU stimulation, with a wide range of iFU stimulation intensity values. In two of the four cases, iFU stimulation generated phantom limb sensations. In addition, we sought to identify the iFU threshold intensity value for the contralateral nerve in three of these four study participants. For two out of those three study participants, iFU stimulation of the intact nerve contralateral to the transected nerve ending did not elicit any sensations. For the remaining study participant, we elicited a sensation, but only once, without successful repetition.
Pain Scores and Their Relation to iFU Stimulation Intensity Value
The LANSS composite pain score measures the overall neuropathic pain level experienced by each study participant. All except two participants had LANSS scores above 12, indicating the likely presence of neuropathic pain in the majority (11/13) of our participants. iFU threshold stimulation intensity values for all patients trended inversely but without statistical significance for the phantom limb pain experienced by the participants over the last 24 hours (R 2 ¼ 0.18, P > 0.05) ( Figure 3A) . Similarly, iFU threshold stimulation intensity values for all patients trended inversely but without statistical significance for the residual limb pain experienced by the participants over the last 24 hours (R 2 ¼ 0.14, P > 0.05) ( Figure 3A) . iFU threshold stimulation intensity values for TNI study participants did have a statistically significant inverse slope as measured against each of the phantom limb and residual limb pain scores (respectively, R 2 ¼ 0.68 and R 2 ¼ 0.55 with P < 0.05; regression lines not shown). In contrast, the same analysis when applied to standard amputation study participants did not show a meaningful trend (respectively, R 2 ¼ 0.008 and R 2 ¼ 0.003 with P > 0.05; regression lines not shown).
Discussion
In this study, we sought to determine if intense focused ultrasound (iFU) could stimulate nerve tissue deep to the skin (a transected nerve ending with or without an observable neuroma in a residual limb) and whether or not nerve tissue in residual limbs is more or less sensitive to iFU stimulation than control tissue. Our results demonstrated that sufficient iFU (the "iFU threshold intensity value") when applied to deep and focal nerve tissue generated discernable sensations in 10 out of 11 test subjects. This included generation of phantom limb sensations in six of those 10 test subjects, more often with a neuroma present (4/6) than not (2/6). Moreover, iFU stimulation of control tissue for a given patient (tissue within a centimeter of the neuroma or nerve ending that lay between the iFU source and its target, a major nerve in the contralateral limb) with the same iFU threshold A B Figure 3 A) iFU threshold stimulation intensity value vs pain scores, each score rated over the last 24 hours: Intensity (w/cm 2 SATA) vs phantom limb pain score (all data R 2 ¼ 0.18). Neither inverse trend achieved statistical significance. B) iFU threshold stimulation intensity value versus pain scores, each score rated over the last 24 hours: Intensity (w/cm 2 SATA) versus residual limb pain score (all data R 2 ¼ 0.14). Neither inverse trend achieved statistical significance.
stimulation intensity value for that patient did not induce a discernable sensation. Finally, for intact, contralateral nerves, we could not identify an iFU threshold stimulation intensity value in six of seven cases (tested up to 1,032 W/cm 2 ) while we generated a sensation due to iFU stimulation only once (not twice in a row) in the remaining test subject.
As a secondary hypothesis, we anticipated that across patients the iFU threshold intensity values would scale inversely with a patient's residual limb and phantom limb pain scores. We observed only a weak and nonstatistically significant inverse correlation for our entire cohort of study participants, leaving this hypothesis falsified thus far.
Potential Clinical Implication of iFU Stimulation
Existing methods for characterizing painful tissue, such as manual palpation, thermodes, lasers, or Peltier devices, stimulate superficial tissue only, or superficial and deep tissue simultaneously. In contrast, iFU can stimulate focal and deep anatomical structures without stimulating the intervening tissue, a potentially useful difference in the clinic setting. When coupled with imaging, the clinician could use iFU to more readily locate and identify deep and tender tissue, a first step in the diagnosis and treatment of a patient's pain. More refined targeting via iFU could in turn motivate application of more refined diagnostic and/or imaging techniques in order to identify the presence and type of peripheral pathology at the site of tenderness. Such identification would then allow for more targeted peripheral interventions such as injections or surgery, if warranted. In the absence of identified peripheral pathology after this extra diagnostic attention, the physician may more readily move to treat potential central contributions to the patient's pain.
Our work offered here represents a first step toward testing the idea that iFU can act as a tool to identify specific peripheral tissues that may act as pain generators in amputee patients. Its use under image guidance may also track the efficacy of pain treatments. Pain management is especially problematic for patients with amputation as residual limb pain and phantom limb pain reduce the quality of life for most adults with amputation. We have shown previously [10] that iFU stimulation threshold values track thermal measures of diurnal variations in inflammatory pain in a rat model. This suggests it is possible that through the use of ig-iFU, a clinician may have the ability to track changes in a patient's pain during treatment. With this in mind, we hypothesize that an increase in iFU stimulation value over time for a given patient may indicate effective pain management, an especially useful finding as clinicians can apply iFU in a way blinded to the patient (and, we assert, blinded to the physician themselves, through design of an appropriate user interface). Interestingly, though not yet the focus of formal study, after targeted muscle reinnervation (TMR) surgery, quite similar to the TNI procedure, [20] patients appear to report less pain than standard amputee patients. Our pilot results suggest that it is possible to use ig-iFU to quantify the sensitivity of transected nerve endings that arise after standard amputation relative to the corresponding nerves at the implantation site of TMR patients, a focus of future study.
It is also possible that the utility of iFU may extend to conditions other than neuromas associated with amputation, such as chronic low back pain. It is well known that current imaging techniques identify abnormalities that often do not correlate with back pain [21] and the presence of abnormal findings on imaging can lead to ineffective or even counter-productive surgical treatments [22] . The use of iFU stimulation could allow clinicians to rule out the presence of specific peripheral pain-generating tissue and may therefore prevent unnecessary surgical interventions. Instead, iFU may help clinicians to more readily attend to central contributors to pain [23, 24] rather than peripheral sources of pain. They may therefore more readily prescribe centrally acting medications, meditation, spinal cord stimulation, psychotherapy, or continued watchful waiting, among other choices [23] .
Future Research
Future studies might consider additional study of the mechanisms by which iFU stimulation may generate sensations. The choices we made of pulse duration and transducer frequency used in this study had their motivation in our existing work [12] , where we applied a single pulse of iFU with a duration of 0.1 seconds to surgically create neuromas in rat legs. Other studies [13, 14, 16, 25] have also investigated sensation induction by single pulses of iFU with a range of ultrasound frequencies (0.3-5.0 MHz) and duration (5-100 ms). By using a single short (0.1 second) pulse, we sought to activate mechanoreceptors, which the literature argues are activated upon ultrasound stimulation of that duration [14, 25, 26] . Future studies should consider application of individual and longer pulses, as applied to a neuropathic rat model by Tych et al. (2013) [9] . In this way, one could refine the study of the physical mechanisms by which ultrasound may generate sensations as a longer pulse may generate heat and activate thermoreceptors at the same time as mechanoreceptors. In addition, future studies might also apply multiple short pulses in rapid succession to study their potential to induce temporal summation and windup, as suggested by Wright et al. (2002) [15] and further explored by McClintic et al. (2013a) [11] .
Finally, in the present, preliminary research, we observed only a weak and statistically insignificant inverse correlation between iFU stimulation intensity value and each of the residual limb pain score and phantom limb pain score for our entire cohort. Interestingly, though quite preliminarily given our patient numbers, we observed divergent results between the TNI and standard amputee study participants. We need to perform additional studies with greater participant numbers to determine if our cohort-based results are intrinsic to iFU stimulation or simply a matter of low patient numbers.
Limitations
One initial goal of this study was to explore the idea that targeted nerve implantation surgery could help reduce neuroma formation and therefore help to reduce amputee pain. Unfortunately, in our small cohort, all of the patients who underwent TNI surgery and participated in our study also had an observable neuroma, as did three of seven of the study participants who underwent standard amputation. We were not, therefore, able to make a meaningful comparison between tissue sensitivity associated with these different surgical procedures, a goal for future studies.
We were also not able to test the sensitivity to iFU stimulation of a major nerve in the intact contralateral limbs of all of our study participants due to patient fatigue. Future studies should consider determination of the stimulation threshold of intact nerves in healthy controls vs amputee patients.
In addition, our current studies allowed for blinding of the patient to iFU stimulation, but not the individual delivering the stimulation. We will seek to rectify this in future research through modification of our device to test the usefulness of delivering iFU stimulation in a doubleblinded fashion.
Finally, as mentioned above, we observed only a weak and statistically insignificant inverse correlation between iFU stimulation intensity value and each of the residual limb pain score and phantom limb pain score for our entire cohort, although the (small) TNI subgroup showed an inverse trend. Perhaps more refined inclusion criteria, the addition of a QST study or, with more study participants, secondary stratification of the data against LANSS score or patient complaint, among other factors, would allow us to identify a subset of patients whose actual iFU threshold value provides additional diagnostic information.
Conclusion
This study builds on our previous work that studied iFU stimulation of neuromas in a rat model [12] . Here, we have conducted a preliminary study of ig-iFU applied to the transected nerve endings of two cohorts of patients with lower extremity amputations-those who have undergone a standard amputation and those who have undergone targeted nerve implantation. We found that the transected nerves in the amputated limbs were more sensitive to iFU stimulation than both local control tissue and the corresponding major nerve in the intact limbs of the same participants. Additionally, we were able to image those targets while performing iFU application, showing successful use of iFU under image guidance.
We have therefore demonstrated the feasibility of noninvasively stimulating transected nerve endings using intense focused ultrasound under image guidance. Future work will explore the potential clinical usefulness of this new means of identifying deep, focal, and tender tissue.
